Enhance your knowledge of CCA by listening to experts give their
perspectives on key topics in the educational videos below*
Company/Organisation | Relationship(s) |
---|---|
AstraZeneca, BMS, EMD Serono, Incyte, Menarini, MSD, Nerviano Medical Science, Novartis, Pierre Fabre, Roche, Sanofi | Consultant/advisory board |
Amgen, BMS, Dephaforum, Healthcare Research & Pharmacoepidemiology, Incyte, Merck KGAA, MSD, Pfizer, Roche, Sanofi, Seagen, Servier | Speaker |
Basilea Pharmaceutica International AG, BMS, Daiichi Sankyo, Exelixis, Roche, Ignyta Operating, Janssen, Kymab, LOXO Oncology, MedImmune, Merck KGAA, Merck Sharp & Dohme Italia Spa, MSD, Novartis, Pfizer, Tesaro | Principal investigator |
Company/Organisation | Relationship(s) |
---|---|
Imaging Equipment Ltd, Ipsen, Novartis, NuCana | Speakers bureau |
Celgene, NuCana | Travel grant |
Agios, AstraZeneca, Debiopharm, Delcath Systems, GenoScience Pharma, Imaging Equipment Ltd, Incyte, Ipsen, Keocyt, Merck, Mundipharma EDO, Novartis, NuCana, PCI Biotech, Pieris Pharmaceuticals, Pfizer, QED, Servier, Wren Laboratories | Grant support |
Company/Organisation | Relationship(s) |
---|---|
Albireo Pharma, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Eisai, GenFit, Nutricia Ipsen, QED, Roche, Servier and TransThera Biosciences | Receipt of honoraria or consultation fees |
AAA, AstraZeneca, Eisai, Incyte, Ipsen, Merck, Pfizer, QED, Roche and Servier | Participation in company-sponsored speaker bureau |
AAA, Bayer, Delcath, Ipsen, Mylan, Novartis, Pfizer and Sirtex | Travel, education funding |
Ipsen and Roche | Research funding |
Company/Organisation | Relationship(s) |
---|---|
Imaging Equipment Ltd, Ipsen, Novartis, NuCana | Speakers bureau |
Celgene, NuCana | Travel grant |
Agios, AstraZeneca, Debiopharm, Delcath Systems, GenoScience Pharma, Imaging Equipment Ltd, Incyte, Ipsen, Keocyt, Merck, Mundipharma EDO, Novartis, NuCana, PCI Biotech, Pieris Pharmaceuticals, Pfizer, QED, Servier, Wren Laboratories | Grant support |
Company/Organisation | Relationship(s) |
---|---|
AbbVie, Agios, Amgen, AstraZeneca, Bayer, BMS, HalioDx, Incyte, Merck Serono, MSD, Pierre Fabre Oncologie, Roche, Sanofi, Servier, Taiho | Consulting/advisory role |
Amgen, AstraZeneca, Bayer, BMS, Foundation Medicine, HalioDx, Incyte, Leo Pharma, Merck Serono, MSD, Pierre Fabre Oncologie, Roche, Sanofi, Servier, Veracyte, Viatris | Honoraria for lectures |
Medscape | Personal fees for a writing engagement |
Travel expenses | Amgen, Bayer, BMS, Merck Serono, MSD, Pierre Fabre Oncologie, Roche, Sanofi, Servier, Viatris |
Company/Organisation | Relationship(s) |
---|---|
Amgen, Basilea, BMS, Incyte, QED Therapeutics, Relay Therapeutics, Servier and Taiho | Safety monitoring or consulting and advisory boards |
Company/Organisation | Relationship(s) |
---|---|
Albireo Pharma, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Eisai, GenFit, Nutricia Ipsen, QED, Roche, Servier and TransThera Biosciences | Receipt of honoraria or consultation fees |
AAA, AstraZeneca, Eisai, Incyte, Ipsen, Merck, Pfizer, QED, Roche and Servier | Participation in company-sponsored speaker bureau |
AAA, Bayer, Delcath, Ipsen, Mylan, Novartis, Pfizer and Sirtex | Travel, education funding |
Ipsen and Roche | Research funding |
Company/Organisation | Relationship(s) |
---|---|
AstraZeneca, BMS, EMD Serono, Incyte, Menarini, MSD, Nerviano Medical Science, Novartis, Pierre Fabre, Roche, Sanofi | Consultant/advisory board |
Amgen, BMS, Dephaforum, Healthcare Research & Pharmacoepidemiology, Incyte, Merck KGAA, MSD, Pfizer, Roche, Sanofi, Seagen, Servier | Speaker |
Basilea Pharmaceutica International AG, BMS, Daiichi Sankyo, Exelixis, Roche, Ignyta Operating, Janssen, Kymab, LOXO Oncology, MedImmune, Merck KGAA, Merck Sharp & Dohme Italia Spa, MSD, Novartis, Pfizer, Tesaro | Principal investigator |
You are now leaving Cholangiocarcinoma-eu.com. This link will take you to a site that is not owned or maintained by Incyte, and Incyte is not responsible for the information contained on third-party sites.
Please select from the following: